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Abstract
Introduction: Designing a radiation plan that optimally delivers both target coverage
and normal tissue sparing is challenging. There are limited tools to determine what
is dosimetrically achievable and frequently the experience of the planner/physician
is relied upon to make these determinations. PlanIQ software provides a tool that
uses target and organ at risk (OAR) geometry to indicate the difficulty of achieving
different points for organ dose–volume histograms (DVH). We hypothesized that
PlanIQ Feasibility DVH may aid planners in reducing dose to OARs.
Methods and materials: Clinically delivered head and neck treatments (clinical plan)
were re-planned (re-plan) putting high emphasis on maximally sparing the contralat-
eral parotid gland, contralateral submandibular gland, and larynx while maintaining
routine clinical dosimetric objectives. The planner was blinded to the results of the
clinically delivered plan as well as the Feasibility DVHs from PlanIQ. The re-plan
treatments were designed using 3-arc VMAT in Raystation (RaySearch Laboratories,
Sweden). The planner was then given the results from the PlanIQ Feasibility DVH
analysis and developed an additional plan incorporating this information using 4-arc
VMAT (IQ plan). The DVHs across the three treatment plans were compared with
what was deemed “impossible” by PlanIQ’s Feasibility DVH (Impossible DVH). The
impossible DVH (red) is defined as the DVH generated using the minimal dose that
any voxel outside the targets must receive given 100% target coverage.
Results: The re-plans performed blinded to PlanIQ Feasibilty DVH achieved supe-
rior sparing of aforementioned OARs compared to the clinically delivered plans and
resulted in discrepancies from the impossible DVHs by an average of 200–700 cGy.
Using the PlanIQ Feasibility DVH led to additional OAR sparing compared to both
the re-plans and clinical plans and reduced the discrepancies from the impossible
DVHs to an average of approximately 100 cGy. The dose reduction from clinical to
re-plan and re-plan to IQ plan were significantly different even when taking into
account multiple hypothesis testing for both the contralateral parotid and the larynx
(P < 0.004 for all comparisons). No significant differences were observed between
the three plans for the contralateral parotid when considering multiple hypothesis
testing.
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Conclusions: Clinical treatment plans and blinded re-plans were found to subopti-
mally spare OARs. PlanIQ could aid planners in generating treatment plans that push
the limits of OAR sparing while maintaining routine clinical target coverage goals.
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1 | INTRODUCTION
Proper optimization of intensity modulated radiation therapy (IMRT)
is central to providing treatments that provide conformal target cov-
erage while sparing normal organs at risk (OARs). Technological
advances in radiation treatment delivery have led to increases in plan
complexity and increased variability in plan quality.1 Clinically, goal
sheets are used routinely to guide IMRT planning in order to ensure
that dosimetric constraints of OARs are met whenever possible.
However, goal sheets do not explicitly provide information regarding
the optimally achievable plan quality for a specific patient, but are
rather a “one-size-fits-all” generic recommendation for critical struc-
ture dose limits. To understand how these dose limits are applied in
clinical practice, it is instructive to examine the IMRT clinical inverse
planning process, which superficially seems quite simple. A planner
dictates target doses and OAR constraints as inputs. An optimizer
then finds the minimum of a cost function incorporating the desired
doses and constraints. In actual practice, inverse planning is consid-
erably more complicated; often requiring “dummy structures” such as
avoidances, shells, and optimization structures along with multiple
rounds of optimization to generate quality plans. Therefore, planning
has become increasingly human/user dependent, which leads to
increasing variability from plans between planners and even within
departments/dosimetry teams. The final plan can also have consider-
able variability because of the planner’s interpretation of the recom-
mended dose limits—some planners may choose to stop sparing
structures when the dose limit is just met, while others may choose
to pursue further sparing after the dose limit is met. Automatic and
knowledge-based planning aids have been developed with the aim
of increasing plan quality while reducing variability.
The variability in plans is particularly true for complex treatment
sites such as the head and neck. This region of the body has an abun-
dance of important and radiation sensitive OARs and frequently
requires treatments of irregularly shaped planning target volumes
(PTVs) with potentially multiple dose prescriptions. One major area of
concern for head and neck treatments is the dosimetric sparing of a
patient’s salivary glands, pharyngeal constrictors, and larynx. High
doses of radiation to these organs can cause dry mouth (xerostomia)
and difficulty swallowing (dysphagia).2–6 Sparing a patient’s salivary
glands and larynx has been shown to reduce symptoms and increase
patient quality of life.2,7–9 The QUANTEC review of dose–volume
effects on salivary function by Deasy et al. concluded that for IMRT
plans the mean dose to each parotid gland should be kept as low as
possible.3 It also states that, “a lower mean dose to the parotid gland
usually results in better function, even for relatively low mean doses
(<1000 cGy).”3 The same review examining larynx and pharynx dose–
volume effects had a similar conclusion stating that planners should
minimize the volume of pharyngeal constrictors and larynx receiving
6000 cGy, and when, possible 5000 cGy.6 Both publications empha-
size the concept of minimizing the dose to these structures beyond
the published/accepted benchmarks (i.e., as low as achievable). How-
ever, in practice, it is difficult to determine if a particular plan has in
fact minimized the dose to these structures using a dose–volume his-
togram (DVH). The minimal dose to an OAR is predominantly dictated
by the geometric relationship between the OAR and PTV(s). PlanIQTM
software (Sun Nuclear, Melbourne, Florida, USA) offers a tool called
Feasibility DVHTM which quantitatively determines regions of a DVH
that are impossible (red), difficult (orange), challenging (yellow), and
probable (green) on a per OAR basis, based on an ideal dose falloff
from the prescription dose at the target boundary. The impossible
DVH (red) is defined as the DVH generated using the minimal dose
that any voxel outside the targets must receive given 100% target cov-
erage. We performed a study comparing salivary gland and larynx
sparing with and without the use of PlanIQ’s Feasibility DVH. We
studied whether PlanIQ’s Feasibility DVH could provide accurate esti-
mates of OAR sparing and whether its use during treatment planning
could facilitate increased sparing of patients’ salivary glands and the
larynx while maintaining target coverage and overall plan quality.
2 | MATERIALS AND METHODS
We identified 10 patients treated on one of two prospective proto-
cols at our institution. All patients had primary lesions of the
oropharynx and were node positive. Patients were originally treated
using Tomotherapy (Accuray, Palo Alto, USA) (field width = 2.5 cm
and pitch = 0.287–0.310) and retrospectively re-planned using
Raystation (RaySearch Medical Laboratories AB, Stockholm, Sweden)
on an Elekta Versa HD (Stockholm, Sweden) using volumetric arc
therapy (VMAT) with three full 6 MV arcs (re-plan) and four full
6 MV arcs (IQ plan). The re-plan treatments were performed blinded
to the results of the clinical plan and PlanIQ Feasibility DVH. For the
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IQ plan, the results from the PlanIQ Feasibility DVH analysis were
available and used during treatment planning.
During planning, the MLC leaf motion was limited to 0.48 cm/de-
gree. The PTVs and OARs used during clinical planning were the same
as used during the re-plan and IQ plan. All OARs were expanded by
3 mm and PTVs pulled in skin 3 mm. A combination of equivalent uni-
form dose (EUD)- and DVH-based planning methods were used. The
high risk PTV (PTV HR) was prescribed to 6000 cGy and the standard
risk PTV (PTV SR) was prescribed 5400 cGy in 200 cGy fractions.
These two plans were delivered using simultaneous integrated boost
(SIB). For the re-plan, a multi-criteria optimization (MCO) was gener-
ated for each patient followed by conversion to a deliverable plan and
additional manual optimization. EUD optimization was used for spar-
ing of OARs. Optimization structures were used for each OAR by sub-
tracting the PTV SR with a 3 mm margin from the OAR. A maximum
EUD (equation below) equal to 100–200 cGy less than the current
average dose was used as a constraint with the “a” parameter equal to








where vi is the partial volume with absorbed dose Di.
This process was repeated until additional sparing was not
achieved or sparing resulted in other plan issues such as hot spots,
failing of clinical goals, etc. that could not be recovered. The goal of
the re-plan was to maximally spare the contralateral parotid, con-
tralateral submandibular gland, and larynx while still meeting our rou-
tinely used clinical goal sheet (Table 1). For the IQ plan, the Sun
Nuclear PlanIQ Feasibility DVH information was made available dur-
ing the planning process. The same (MCO) was performed; however,
rather than iteratively reducing the optimization constraints for the
OARs, the mean value derived from the impossible DVH was used
as the criteria for the max EUD with the “a” parameter equal to one.
The EUD with the “a” parameter equal to one is equivalent to the
mean dose. The re-plan was performed blinded to the results of the
clinically delivered plan as well as the Feasibility DVH information
from PlanIQ. The IQ plans were performed aware of the Feasibility
DVH information. The IQ plans were not compared to the clinically
delivered plan nor the re-plan during the planning process. A sum-
mary of the generated plans is shown in Table 2.
The Feasibility DVHs were generated by exporting the simulation
CT and patient structures to PlanIQ. In PlanIQ, the PTVs were assigned
their respective prescription doses and the Feasibility DVHs were calcu-
lated for 6 MV beams and a dose grid size of 2 mm using the maximal
falloff method. The Feasibility DVHs are calculated using energy-specific
high gradient dose spread (HGDS) kernel assuming the entire PTV is
receiving prescription. All neighboring voxels within a distance deter-
mined by the HGDS are searched, and if they are target surface voxels,
their distance away (or radiological distance, if heterogeneity corrections
are employed) and dose level produce a dose spread value at all nontar-
get voxels. A low dose spread (LDS) process adds a minimal low dose
that must occur due to scatter and transmission assuming beams from
many angles, 360° around the targets. Again, on a voxel-by-voxel basis,
it estimates a minimal dose that must occur at any given voxel outside
the targets, assuming 100% coverage and given the target sizes, shapes,
and dose levels. Two low dose spread kernels are generated dynamically
(based on nominal energy and target volume), one for near and far dis-
tances, and are used to convolve the original 3D target doses into two
low dose 3D grids. There is energy-dependent postprocessing of each
LDS grid to further morph the lower dose values and to apply correc-
tions in regions of low patient density. Then, for each LDS grid and for
each nontarget voxel, the LDS value is compared to the current dose
using the HGDS at all voxels, and if it is higher, then it replaces the cur-
rent value in the benchmark grid. PlanIQ does not require any knowl-
edge about the delivery technique or commissioning data.
The mean dose according to the impossible region of the Feasi-
bility DVH was compared to the re-planned and clinical mean dose
for each of the three OARs mentioned previously. This comparison
was performed postplanning for the re-plan as it was blinded to the
Feasibility DVH. The distribution of mean doses was not normally
distributed based on the Shapiro–Wilk test of normality. Therefore, a




PTV HR ≥6000 cGy V95%
PTV HR ≥5550 cGy V99%
PTV HR 0.75 Conformity indexa
PTV SR ≥5400 cGy V95%
PTV SR ≥5022 cGy V99%
PTV SR 0.75 Conformity indexa
Brainstem + 3 mm ≥5400 cGy Dose to 0.1 cc
Cochlea + 3 mm
(applies to both cochleas)
≥4500 cGy Mean dose
Cord + 3 mm ≥5000 cGy Dose to 0.1 cc
Larynx + 3 mm ≥4100 cGy Mean dose
Larynx + 3 mm ≥6000 cGy D24%
Normal Tissue
(skin minus PTV SR)
≥5940 cGy D1%
Contralateral Parotid + 3 mm ≥2600 cGy Mean dose
Contralateral Parotid + 3 mm ≥3000 cGy D50%
Contralateral
Submandibular + 3 mm
≥3500 cGy Mean dose
aDefined as volume of the associated PTV divided by the volume of the
prescription isodose line.









N/A Tomotherapy Tomotherapy DVH-based
Re-plan YES Raystationa Versa HD EUD/DVH-based
IQ Plan YES Raystationa Versa HD EUD/DVH-based
aRaystation used mutlicriteria optimization.
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paired Wilcoxon sign rank test was used to determine statistical sig-
nificance between plans. A Bonferroni correction was used in order
to account for multiple hypothesis testing (P < 0.008 was needed
for significance).
All plans were determined if they would be “clinically deliverable”
by the attending physician for these patients. The process of deter-
mining clinical deliverability was performed in the same manner as
initial approval in that the physician reviewed the plan in all slices
examining both DVH constraints as well as overall plan quality (i.e.,
no obvious hotspots outside the PTVs, reduced dose to the posterior
neck and oral avoidances, etc.). To ensure that the generated plans
were deliverable, our clinical IMRT QA procedure was performed on
all IQ plans. A 3D diode array (ArcCHECK, Sun Nuclear, Melbourne,
FL) was used to measure the machine delivered dose and SNC
patient software (version 6.1.0; Sun Nuclear, Melbourne, FL, USA)
was used to calculate the gamma pass rate using a global criteria of
3%/3 mm. At our institution, the standard criteria pass rate that we
deem a plan acceptable for treatment is greater than 90%.
3 | RESULTS
All plans passed our institutional IMRT QA standard (range: 92.8%–
98.6%). The comparison between the mean dose from the clinical,
re-plan, and IQ plans to the impossible boundary from the Feasibility
DVH (Impossible DVH) are shown in Fig. 1. The re-plans were able
to provide increased sparing of OARs compared to the delivered
plans and subsequently agreed better with the mean dose from
Impossible DVH. The contralateral parotid and larynx were spared
for all patients in both the clinically delivered plan and the re-plan.
On average, the re-plan reduced the dose compared to the clinical
plan by approximately 750 cGy and 600 cGy for the contralateral
parotid and larynx, respectively. For patients whose contralateral
submandibular gland was spared in the clinical plan (7/10 patients),
the re-plans reduced the mean dose by approximately 300 cGy.
The IQ plans were found to reduce the mean dose to the con-
tralateral parotid and larynx by approximately 1130 cGy (range:
890–1460) and 1180 cGy (range: 550–1890), respectively compared
to the clinically delivered plans and 370 cGy (range: 20 to 690)
and 560 Gy (range: 300–1090), respectively compared to the re-
plans. These values correspond to percent reductions of 50% and
34%, respectively compared to the clinically delivered plans and 24%
and 19%, respectively compared to the re-plans. The dose reduction
from clinical to re-plan and re-plan to IQ plan were significantly dif-
ferent even when taking into account multiple hypothesis testing for
both the contralateral parotid and the larynx (P < 0.004 for all com-
parisons). No significant differences were observed between the
three plans for the contralateral parotid when considering multiple
hypothesis testing. The sparing of the contralateral submandibular
gland was relatively consistent across all plans. The average dose
delivered to the larynx, contralateral parotid, and contralateral sub-
mandibular glands were on average within approximately 100 cGy of
the predicted impossible DVH from PlanIQ. The DVHs for patient
10 compared to the Feasibility DVH are shown in Fig. 2 for each of
the analyzed OARs.
4 | DISCUSSION
The 10 retrospective re-plans were performed in order to determine
how close one could come to what PlanIQ deemed impossible using
the Feasibility DVH. The average difference between re-planned
mean doses and the mean calculated from the Impossible DVH were
672 cGy, 416 cGy, and -248 cGy for the larynx, contralateral paro-
tid, and contralateral submandibular gland, respectively. The IQ plans
were then performed to determine if having the knowledge of Feasi-
bility DVH during planning allowed for higher agreement and subse-
quently enhanced OAR sparing. We found that incorporating what
the Feasibility DVH deemed the threshold of impossible into plan-
ning yielded dosimetry with very high agreement between planned
and predicted sparing (<300 cGy for all patients and all OARs exam-
ined; approximately 100 cGy on average). Both the re-plans and IQ
plans found that substantial sparing was possible compared to what
was clinically delivered. However, the fact that re-plans were found
to increase sparing is not surprising as they were performed without
additional clinical load, time constraints, etc. that are experienced
clinically by dosimetrists. What is surprising is the magnitude of the
improvement in sparing between the clinical plans and the IQ plans.
Reducing the dose to the contralateral parotid and larynx by
~1200 cGy could potentially lead to a meaningful improvement in
patient toxicity/symptom burden.
This study demonstrates that planners could use the Feasibility
DVH to guide dosimetric constraints during planning to ensure plans
have been adequately optimized. Overall, the average difference
between re-planned and impossible DVH was found to be within
200–700 cGy for the salivary glands and larynx when blinded to Pla-
nIQ’s Feasibility DVH and approximately 100 cGy when this infor-
mation is available during planning. The achieved doses were
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F I G . 1 . Comparing difference between clinical, re-plan, and IQ
plan versus Impossible DVH.
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sometimes less than the Impossible DVH; however, this was found
to be due to under dosing of the PTV (predominantly the PTV SR).
As our routine prescription is to 95% coverage of PTVs, under dos-
ing is permitted in OAR overlap regions while planning, but not
accounted for in PlanIQ. This is why the re-planned contralateral
submandibular mean doses fall below the predicted impossible mean.
PlanIQ’s Feasibility DVH could also be used as a plan quality tool
where clinicians could make sure that plan DVHs fall within a certain
range from the impossible threshold. The impossible DVH could also
be a useful tool in determining what constraints cannot be met with-
out compromising PTV coverage which would save planning time
trying to optimize to constraints that are not achievable. Current
practice relies on a single pass/fail Criterion when determining plan
acceptability. Having a prediction of what is achievable would allow
for constraints that are dependent on individual patient target/OAR
geometry and would enable a higher degree of treatment personal-
ization and optimization.
Other planning aids, such as RapidPlan and Autoplan, are avail-
able to aid clinicians in a similar manner. However, knowledge-based
planning tools such as RapidPlan are dependent on the database of
plans that are being used for reference. The plans included in model
libraries may be consistent with what has been historically delivered,
but may not be representative of what is dosimetrically achievable/
optimal. A study by Tol et al. found that there were strong correla-
tions between predicted and achieved mean doses when using Rapid-
Plan.10 However, this does not address whether the data from these
types of tools led to near-optimal sparing of OARs. Autoplan is
another aid designed to help planners to optimize treatments; how-
ever, realistic and achievable constraints are still necessary. PlanIQ’s
Feasibility DVH is based entirely on prescribed dose and contour
geometry and therefore has no dependence on variation within a
model library of previously generated plans. Our study demonstrated
reasonable agreement between the PlanIQ impossible DVH and the
IQ plans with average deviation being in the range of 100 cGy for
the contralateral parotid, contralateral submandibular gland, and lar-
ynx. The ability to generate realistic constraints is beneficial on its
own and may even improve the functionality of other planning aids
such as RapidPlan and Autoplan.
While PlanIQs calculations are only dependent on target/OAR
geometry, beam energy, and CT density, they do not take into
account delivery method or under dosing of PTVs. PlanIQ bases its
calculations purely on maximum falloff from the target(s) and there-
fore may underappreciate difficulty in actual treatment delivery
when many competing OARs are involved or if an OAR is particu-
larly large (e.g., bone marrow, bowel space, etc.). The low dose
spread components were fit based on phantom cases and validated,
in part, based on the methods by Ahmed et al. (in press) (i.e., opti-
mize a plan to give 100% coverage and spare only one critical OAR
at a time, then compare the achieved DVH to Impossible DVH). Our
results found that PlanIQ performed well in head and neck cases at
providing useful information that planners could use to increase plan
quality even in the presence of multiple OARs. It may be unrealistic
to think all OARs will have attainable DVHs in close proximity to
their corresponding impossible DVH but the data do show that the
impossible DVH does represent a good baseline for possible sparing.
Furthermore, it was noted that additional dose was given to regions
of the posterior skull base, mandible, and posterior neck in the IQ
plans compared to the clinically delivered plans. The clinical plans
were also found to have less heterogeneity within the PTVs com-
pared to the IQ plans. However, no plans contained a PTV HR hot
spot greater than 109% of the Rx. Nevertheless, all plans were con-
sidered clinically deliverable by the attending physician for these
patients.
The fact that PlanIQ does not consider beam delivery can be
seen as a positive in some ways when comparing to knowledge-
based tools. Knowledge-based planning may lose accuracy if the
implemented delivery is different from the treatments included in
the model library, whereas calculation-based methods such as Pla-
nIQ’s Feasibility DVH do not have this added component of
variability.
An additional cofounding factor besides clinical load, time con-
straints, etc. that makes comparison between the clinical plan, re-
plan, and the IQ plan difficult is that the two were planned on differ-
ent machines (Tomotherapy versus Versa) and different treatment
planning systems (Tomotherapy versus Raystation). Tomotherapy
was used to treat all patients in this cohort originally and our
F I G . 2 . Patient 10 Feasibility DVH for larynx, contralateral parotid, and contralateral submandibular comparing the clinical, re-plan, and IQ
plan DVHs.
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institution has subsequently has shifted to predominantly using
Raystation and therefore this was of more clinical interest. In terms
of the results, we view that our major finding is not the quantitative
reduction in sparing achieved between the clinical to IQ plans, but
the proximity by which the IQ plan adheres to the predictions pro-
vided by the feasibility DVH (<2 Gy). The purpose of including the
clinical plans was to illustrate that plans that pass our routine clinical
goals and are deemed appropriate for patient delivery can often be
improved. Anecdotally, in our clinical practice we have not observed
drastic discrepancies plan quality or ability to achieve Feasibility
DVH criteria between Tomotherapy planning versus Raystation/
Versa planning. The IQ plans were shown to be deliverable and pro-
vided additional sparing of the salivary structures and larynx even
when compared to the re-plans using the same treatment planning
system and machine. These results realistically present two different
planning paradigms that need clinical consideration. The clinical plans
were delivered with more homogeneous target doses and better low
dose conformity, whereas the IQ plans had superior OAR sparing
but more heterogeneous target doses and inferior low dose confor-
mity in certain areas. Our institution is a high volume, academic cen-
ter that is an active participant in head and neck clinical trials.
Despite these credentials, we were surprised to see how much
higher our OAR doses were compared to those predicted by PlanIQ.
Subsequently, the IQ plans were able to demonstrate that these pre-
dictions were quite accurate in terms of what could be delivered.
These results have led us to begin incorporating PlanIQ into our rou-
tine clinical planning processes.
In the future, our institution hopes to continue to utilize PlanIQ
and to standardize methods by which this information is incorpo-
rated into the planning process. While we utilized 3 and 4-arc VMAT
for this research, we have yet to determine if similar plans could be
generated with few arcs in order to optimize clinical throughput. We
also intend to investigate whether PlanIQ can not only improve plan
quality but also if it may result in a reduction of planning time by
providing reasonable estimates of expected DVHs upfront in the
planning process. Evaluation of PlanIQ needs to be performed for
sites other than head and neck.
Tools capable of providing predictions of what is dosimetrically
achievable (and ideally optimal) are greatly needed in radiation treat-
ment planning in order to reduce plan variability and ensure quality.
This work demonstrates for the first time that PlanIQ’s Feasibility
DVH agrees well with head and neck treatment plans that attempted
to maximally spare salivary glands and the larynx. The addition of
the Feasibility DVH information during planning led to an increased
sparing of OARs compared to both clinical plans and plans blinded
to this information. This suggests the Feasibility DVH could be a
useful tool during planning and as a plan quality assurance tool. In
the future, quantitative predictions such as the Feasibility DVH may
be used in tandem with knowledge-based or auto-planning to pro-
vide the best of both worlds in terms of a tool that can address Fea-
sibility, optimality, and deliverability. Additional studies are needed
examining the incorporation of Feasibility DVHs during treatment
planning and whether it could also lead to increases in clinical effi-
ciency.
CONFLICT OF INTEREST
Departmental research agreement with Sun Nuclear.
REFERENCES
1. Nelms BE, Robinson G, Markham J, et al. Variation in external beam
treatment plan quality: an inter-institutional study of planners and
planning systems. Pract Radiat Oncol. 2012;2:296–305.
2. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing inten-
sity modulated versus conventional radiotherapy in head and neck
cancer (PARSPORT): a phase 3 multicentre randomised controlled
trial. Lancet Oncol. 2011;12:127–136.
3. Deasy JO, Moiseenko V, Marks L, Chao KSC, Nam J, Eisbruch A.
Radiotherapy dose-volume effects on salivary gland function. Int J
Radiat Oncol Biol Phys. 2010;76:S58–S63.
4. Gensheimer MF, Liao JJ, Garden AS, Laramore GE, Parvathaneni U.
Submandibular gland-sparing radiation therapy for locally advanced
oropharyngeal squamous cell carcinoma: patterns of failure and
xerostomia outcomes. Radiat Oncol. 2014;9:255.
5. Little M, Schipper M, Feng FY, et al. Reducing xerostomia after
chemo-IMRT for head-and-neck cancer: beyond sparing the parotid
glands. Int J Radiat Oncol Biol Phys. 2012;83:1007–1014.
6. Rancati T, Schwarz M, Allen AM, et al. Radiation dose-volume
effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys.
2010;76:S64–S69.
7. Dornfeld K, Simmons JR, Karnell L, et al. Radiation doses to struc-
tures within and adjacent to the larynx are correlated with long-term
diet- and speech-related quality of life. Int J Radiat Oncol Biol Phys.
2007;68:750–757.
8. Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Sten-
mark MH. Long-term quality of life after swallowing and salivary-
sparing chemo-intensity modulated radiation therapy in survivors of
human papillomavirus-related oropharyngeal cancer. Int J Radiat
Oncol Biol Phys. 2015;91:925–933.
9. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradio-
therapy aiming to reduce dysphagia in patients with oropharyngeal
cancer: clinical and functional results. J Clin Oncol. 2010;28:2732–
2738.
10. Tol JP, Delaney AR, Dahele M, Slotman BJ, Verbakel WFAR. Evalua-
tion of a knowledge-based planning solution for head and neck can-
cer. Int J Radiat Oncol Biol Phys. 2015;91:612–620.
11. Ahmed S, Nelms B, Gintz D, et al. A method for a priori estimation of
best feasible DVH for organs-at-risk: Validation for head and neck
VMAT planning. Med Phys. 2017. https://doi.org/10.1002/mp.12500.
250 | FRIED ET AL.
